Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 07, 2007. The document serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically detailing changes in interests in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to executive compensation transactions and does not contain consolidated financial statements.
Material Changes
The filing reports the following specific transaction for Mr. D. Stout on December 06, 2007:
- Option Exercise: Exercise of 294,416 ADSs granted under the Share Option Plan.
- Grant Details: Options originated from grants dated May 20, 1998 ($49.36), December 03, 2002 ($37.25), and December 15, 2003 ($44.57).
- Share Sale: Sale of 294,416 ADSs at a price of $52.66 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of insider trading activity in compliance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of ADSs exercised and sold by Mr. D. Stout (294,416 units).
- Confirm the sale price of $52.66 per ADS against market data for December 06, 2007.
- Review the original grant dates and option prices to calculate the realized gain on the transaction.
- Note that this filing does not reflect the company's overall financial performance for the period.